Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
COMPENSATION 2026
ABOUT
PRICE TARGET
UPCOMING EARNINGS
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-01-02 | Reverse | 1:30 |
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$1.10 ▲ UP 1.85% (+$0.02)About Co-Diagnostics, Inc.
https://co-dx.com ↗Co-Diagnostics, Inc. develops and sells molecular diagnostic reagents and platforms for detecting infectious diseases, cancer, and agricultural traits globally, including portable PCR devices for point-of-care and at-home testing.
INDUSTRY
A PRODUCT CO-DIAGNOSTICS, INC. IS KNOWN FOR
The Co-Dx PCR Platform is a portable, at-home and point-of-care molecular diagnostics system, serving as Co-Diagnostics' flagship product to make PCR testing more accessible, pending regulatory approval.
Co-Diagnostics in 2025
Co-Diagnostics Initiates Clinical Evaluations for Multiplex Respiratory Test, Fueling Significant Stock Surge
Co-Diagnostics announced the commencement of clinical evaluations for its Co-Dx™ PCR Flu A/B, COVID-19, RSV Test Kit. This was a pivotal step towards seeking U.S. FDA 510(k) clearance for its point-of-care diagnostic platform, the Co-Dx PCR Pro™, leading to a significant positive market reaction and heightened investor interest.
Co-Diagnostics Establishes Joint Venture for Expansion into Middle East and North Africa
Co-Diagnostics signed a definitive agreement in October 2025 to form a joint venture, CoMira Diagnostics, in Saudi Arabia. This strategic move is intended to manufacture and distribute the company's Co-Dx™ PCR platform and other diagnostic products across the Middle East and North Africa (MENA), a large and growing market for medical devices.
RATINGS SNAPSHOT
Overall rating: B-
MOST RECENT ANALYST GRADES
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 DWTX | $1.61 | COMPARE |
 SINT | $2.17 | COMPARE |
 NVNO | $7.75 | COMPARE |
 AEMD | $6.50 | COMPARE |
 ADGM | $0.14 | COMPARE |
 VVOS | $0.16 | COMPARE |
 XAIR | $2.88 | COMPARE |
 TNON | $3.70 | COMPARE |